Clinical Study on Antiatherosclerotic Effect of Calucium Channel Blocker Azelnidipine in Patients with Essential Hypertension
|
Accession number;07A0026931
|
| Title;Clinical Study on Antiatherosclerotic Effect of Calucium Channel Blocker Azelnidipine in Patients with Essential Hypertension |
| Author;
YAMAKADO MINORU
(Mitsui Memorial Hospital, JPN)
ISHIZAKA YUKO
(Mitsui Memorial Hospital, JPN)
TAIRA MOTOHISA
(Mitsui Memorial Hospital, JPN)
YANO MASAO
(Mitsui Memorial Hospital, JPN)
|
Journal Title;Ther Res
|
Journal Code:Y0681A
|
ISSN:0289-8020
|
|
VOL.27;NO.11;PAGE.2097-2104(2006)
|
| Figure&Table&Reference;FIG.11, TBL.1, REF.29 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;To assess the antiatherosclerotic effect of azelnidipine, changes in not only blood pressure and pulse rate, but also carotid intima-media thickness (IMT) and pulse wave velocity (PWV) as a marker for atherosclerosis, plasma lipid peroxides(LPO), 8-iso prostane, and glycated albumin (GA) as a marker for glycoxidative stress and urinary microalbumin excretion (u-Alb) and high sensitive C-reactive protein (hs-CRP) as a marker for hypertensive organ damages to azelnidipine were determined in 24 patients with essential hypertension before and after the treatment of 16 mg of azelnidipine. Also, the changes in plasma adiponectin and insulin index as HOMA-IR were determined. Azelnidipine significantly decreased blood pressure associated with significant decrement of pulse rate. Carotid IMT and PWV were significantly decreased after the treatment. Also, LPO, 8-iso prostane and GA were significantly decreased, respectively. U-Alb and hs-CRP were also significantly decreased. These results suggest that azelnidipine may have antiatherosclerotic effect as "beyond blood pressure control" through its effects on anti-glycoxidative and anti-inflammatory effect. Also, pulse rate reduction to azelnidipine may participate in the mechanism of azelnidipine on antiatherosclerotic effect. (author abst.) |
|
|
|
Related Articles;
|
|
